MedTrace Logo

DESOLO - SiT Peri-Launch: A Comparison of Symbicort Single Inhaler Therapy and Conventional Best Practice for the Treatment of Persistent Asthma in Adults

NCT00252863 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1600

Last updated 2009-03-17

No results posted yet for this study

Summary

The purpose of this study is to determine whether Symbicort dosed according to the Symbicort Maintenance and Reliever Therapy (SMART) concept is superior to standard asthma treatment according to the local German treatment guidelines.

Conditions

Interventions

DRUG

Symbicort, used twice daily (b.i.d) and as needed (prn)

DRUG

Budesonide Turbuhaler 200 µg

DRUG

Fluticasone Discus 250 µg

DRUG

Formoterol Turbuhaler 4.5 µg

DRUG

Terbutaline Turbuhaler 0.5 mg

DRUG

Salbutamol pressurized metered dose inhaler (pMDI) 100 µg

DRUG

Salmeterol Discus 50 µg

DRUG

Budesonide/Formoterol Turbuhaler 160/4.5 µg

DRUG

Fluticasone/Salmeterol Discus 250/50 µg

DRUG

Fluticasone/Salmeterol Discus 500/50 µg

DRUG

Theophylline 200 mg

DRUG

Theophylline 300 mg

DRUG

Singulair 10 mg

Sponsors & Collaborators

Principal Investigators

  • Heinrich Worth, MD · Klinikum Fürth

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-12-31
Completion
2006-05-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00252863 on ClinicalTrials.gov